Affiliation:
1. Federal state budgetary scientific institution "Mental health research center"
2. Russian Medical Academy of Continuous Professional Education
Abstract
Introduction. The presence of the active metabolite (3-hydroxyphenazepam, 3-OH-PHEN), the wide interindividual variability of the therapeutic effect of phenazepam (PHEN), as well as its active moiety in the blood, determine the relevance of therapeutic drug monitoring (TDM). To do this, the researcher must have an express analytical technique with a wide analytical range, a low limit of quantification (LLOQ), and with robustness with different sample preparation methods.Aim. Development and validation of quantitative methods for PHEN and 3-OH-PHEN in human blood plasma with different sample preparation methods.Materials and methods. The determination of PHEN and 3-OH-PHEN has been performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Solid-phase extraction (SPE) and liquid extraction with support (SLE) otherwise called liquid-liquid extraction in the solid phase were used for sample preparation. Metoprolol was utilized as an internal standard (IS). Gradient elution profile between mobile phase A (0.2 % aqueous formic acid) and B (100 % acetonitrile) has been used. Column: Hypersil GOLD® C18, 50 × 2.1 mm, 3.5 μm.Results and discussion. Two methods have been developed for the quantitative determination of PHEN and 3-OH-PHEN in human blood plasma using different sample preparation methods: SPE and SLE. The conditions of chromatographic separation and mass spectrometric detection of the analytes are selected. The following validation characteristics were determined for both methods: selectivity, calibration curve, accuracy, precision, degree of extraction, LLOQ, carry-over effect, matrix factor, stability of standard solutions and analyte in the matrix.Conclusion. The validation results of the developed methods meet the established criteria, which allows them to be used for the quantitative determination of PHEN and 3-OH-PHEN in human blood plasma. The wide analytical range for both methods 1–1000.00 ng/ml allows the use them for pharmacokinetics and bioequivalence studies, as well as in toxicology.
Publisher
Center of Pharmaceutical Analytics Ltd
Reference20 articles.
1. Moosmann B., Huppertz L. M., Hutter M., Buchwald A., Ferlaino S., Auwärter V. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. Journal of Mass Spectrometry. 2013;48(11):1150–1159.
2. Voronina T. A., Seredenin S. B. Prospects of search for new anxiolytics. Éksperimentalnaya i Klinicheskaya Farmakologiya. 2002;65(5):4–17. (In Russ.)
3. Gorodnichev A. V., Kostyukova E. G. The place of phenazepam in the modern use of benzodiazepine tranquilizers. Current Therapy of Mental Disorders. 2011;2:26–29 (In Russ.)
4. Seredenin S. B., Voronina T. A., Neznamov G. G., Zherdev V. P. Phenazepam: 25 years in medical practice. Moscow: Nauka; 2007. 222 p. (In Russ.)
5. Osadshiy Y. Y., Voblenko R. A., Archakov D. S., Tarakanova E. A. Benzodiazepines. An attempt to arrive at an informed consensus. Current Therapy of Mental Disorders. 2016;1:2–10. (In Russ.)